TY - JOUR
T1 - Effects of 7, 8-benzoflavone on skin tumor-initiating activities of various 7- and 12-substituted derivatives of 7, 12-dimenthylbenz[a]anthracene in mice
AU - Di Giovanni, J.
AU - Slaga, T. J.
AU - Harvey, R. G.
N1 - Funding Information:
1 Received August 29, 1977; accepted February IS, 1978. 2 Supported in part by Public Health Service (PHS) grant HD04839 from the National Institute of Child Health and Human Development, PHS grant CAI9448 from the National Cancer Institute, PHS training grant GMOO109 from the National Institute of General Medicine Sciences, and by the Energy Research and Development Administration under contract with Union Carbide Corporation. , Department of Pharmacology, University of Washington, School of Medicine, Seattle, Wash. 98105. • Biology Divison, Oak Ridge National Laboratory, Oak Ridge, Tenn. 37830. , Ben May Laboratory for Cancer Research, University of Chicago, Chicago, Ill. 60637. 6 We thank Moses J. Namkung for his technical assistance in the synthesis of [,HJ7-bromomethyl-12-methylbenz[aJanthracene.
PY - 1978/7
Y1 - 1978/7
N2 - The skin tumor-initiating activities of various 7- and 12-substituted derivatives of 7, 12-dimethylbenz[a]anthracene (dmba) were investigated in female outbred charles river cd-1 mice. 7-formyl-12-methylbenz[a]anthracene (7-cho-12-mba) at 740 nmoles/mouse was an effective tumor initiator, at a dose 74fold greater than that of dmba. 7, 8-benzoflavone (7, 8-bf) inhibited the tumor-initiating activity of 7-cho-12-mba by 51%. 12-formyl-7-methylbenz[a]anthracene and 7, 12-diformylbenz[a]- anthracene, applied at initiating doses of 740 nmoles and 704 nmoles/mouse, respectively, were much less active than 7-cho- 12-mba. 7-bromomethyl-12-methylbenz[a]anthracene (7-brme- 12-mba) and 7-bromomethylbenz[a]anthracene (7-brmeba) were also investigated. 7-brme-12-mba was a more effective tumor initiator than 7-brmeba, but both were less active than dmba. 7, 8-bf inhibited the tumor-initiating activity of 7-brme- 12-mba and 7-brmeba by 34 and 54%, respectively. 12- bromomethyl-7-methylbenz[a]anthracene (12-brme-7-mba) was as active an initiator as 7-brme-12-mba. 7, 8-bf inhibited tumor initiation with 12-brme-7-mba by 29%. three naturally occurring flavones, quercetin, myricetin, and 4', 5, 7-trihydroxy- flavonone, and the cytochrome p450; inhibitor 1-benzylimidazole were investigated after topical application (100 µg) for their effects on tumor initiation with dmba. quercetin inhibited tumor initiation with dmba by 22%, whereas myricetin and 4', 5, 7- trihydroxyflavanone enhanced tumor initiation with dmba by 54 and 29%, respectively. 1-benzylimidazole had no effect. the abilities of the flavones and 1-benzylimidazole to inhibit aryl hydrocarbon hydroxylase in vitro did not correlate with their effects on tumor initiation with dmba.-j natl cancer inst 61: 135-140, 1978.
AB - The skin tumor-initiating activities of various 7- and 12-substituted derivatives of 7, 12-dimethylbenz[a]anthracene (dmba) were investigated in female outbred charles river cd-1 mice. 7-formyl-12-methylbenz[a]anthracene (7-cho-12-mba) at 740 nmoles/mouse was an effective tumor initiator, at a dose 74fold greater than that of dmba. 7, 8-benzoflavone (7, 8-bf) inhibited the tumor-initiating activity of 7-cho-12-mba by 51%. 12-formyl-7-methylbenz[a]anthracene and 7, 12-diformylbenz[a]- anthracene, applied at initiating doses of 740 nmoles and 704 nmoles/mouse, respectively, were much less active than 7-cho- 12-mba. 7-bromomethyl-12-methylbenz[a]anthracene (7-brme- 12-mba) and 7-bromomethylbenz[a]anthracene (7-brmeba) were also investigated. 7-brme-12-mba was a more effective tumor initiator than 7-brmeba, but both were less active than dmba. 7, 8-bf inhibited the tumor-initiating activity of 7-brme- 12-mba and 7-brmeba by 34 and 54%, respectively. 12- bromomethyl-7-methylbenz[a]anthracene (12-brme-7-mba) was as active an initiator as 7-brme-12-mba. 7, 8-bf inhibited tumor initiation with 12-brme-7-mba by 29%. three naturally occurring flavones, quercetin, myricetin, and 4', 5, 7-trihydroxy- flavonone, and the cytochrome p450; inhibitor 1-benzylimidazole were investigated after topical application (100 µg) for their effects on tumor initiation with dmba. quercetin inhibited tumor initiation with dmba by 22%, whereas myricetin and 4', 5, 7- trihydroxyflavanone enhanced tumor initiation with dmba by 54 and 29%, respectively. 1-benzylimidazole had no effect. the abilities of the flavones and 1-benzylimidazole to inhibit aryl hydrocarbon hydroxylase in vitro did not correlate with their effects on tumor initiation with dmba.-j natl cancer inst 61: 135-140, 1978.
UR - http://www.scopus.com/inward/record.url?scp=0017886161&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017886161&partnerID=8YFLogxK
U2 - 10.1093/jnci/61.1.135
DO - 10.1093/jnci/61.1.135
M3 - Article
C2 - 97391
AN - SCOPUS:0017886161
VL - 61
SP - 135
EP - 140
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
SN - 0027-8874
IS - 1
ER -